The Clap SPIMACO’s subsidiary “Dammam Pharma” has signed a strategic alliance agreement with the global company “Merck Sharp & Dohme.”
This collaboration aims to manufacture type 2 diabetes medicines in Saudi Arabia, with production scheduled to begin in the first quarter of the upcoming year.
What Spimaco stated that the agreement aims to meet the Kingdom’s demand for type 2 diabetes medicines. In addition, the production will cater to regional markets, positioning itself as the first factory in MENA.
So What The “Diabetes Medicines Project” aligns with “Vision 2030,” aiming to support the national industry strategy. It seeks to localize the pharmaceutical industries, enhancing health and drug security in the country.
Now What The project is expected to provide opportunities for transferring high-specialized pharmaceutical technologies.